2021/02/03 | Research | In-vitro & Organs-on-Chip
The Integrated Actuators Laboratory, École Polytechnique fédérale de Lausanne (EPFL) in collaboration with the ARTORG Cardiovascular Engineering group has developed and tested a dielectric‐elastomer actuator (DEA) for the aorta that can assist patients with heart failure and offer a potential alternative to heart transplantation. In vitro experiments using a pulsatile flow‐loop showed the DEA reduced the energy that the heart has to exert by 5 percent and is driven by the physiological pressure of the aorta itself.
In the study a team of engineers and clinicians presented the first dielectric‐elastomer‐augmented aorta (DEAA), consisting of a tubular DEA with an electrically driven compliance. It is designed to assist the pulsatile nature of the heart by means of an innovative aortic counter‐pulsation approach. The possibility of an electrically driven counterpulsation device paves the way for a fully implanted device (not possible for current pneumatically driven aortic counterpulsation devices) and for a high‐level cardiac assistance.
“The advantage of our system is that it reduces the pressure on a patient’s heart. The idea isn’t to replace the heart, but to assist it,” says Yoan Civet, a Scientist at the EPFL’s Integrated Actuators Laboratory. The study was supported by the Werner-Siemens Stiftung.
Link to the study
Media release EPFL, 3 February 2021
Further information on the project
Cardiovascular Engineering, ARTORG Center